中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 7
Jul.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(7): 1594-1598

Effectiveness and safety of ultrasound-guided ablation in treatment of primary liver cancer in dangerous areas

DOI: 10.3969/j.issn.1001-5256.2021.07.023
  • 1.

    Graduate School, Tianjin Medical University, Tianjin 300070, China

  • 2a.

    Department of Hepatology, Tianjin Second People's Hospital, Tianjin 300192, China

  • 2b.

    Department of Ultrasound, Tianjin Second People's Hospital, Tianjin 300192, China

  • 3.

    Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

Research funding:

Health Commission of Tianjin Science and Technology Fund Project (2014KZ009);

Tianjin Second People's Hospital Scientific Research Fund Project (YS-0012)

  • Received Date: 2020-11-13
  • Accepted Date: 2021-01-27
  • Published Date: 2021-07-20
    Abstract
  •   Objective  To investigate the effectiveness and safety of ultrasound-guided percutaneous local ablation in the treatment of liver cancer in dangerous areas.  Methods  A total of 179 patients with primary liver cancer who were admitted to Tianjin Second People's Hospital from January 2014 to September 2017 and underwent ultrasound-guided ablation for the first time were enrolled, and according to tumor location, the patients were divided into dangerous area group with 134 patients and non-dangerous area group with 45 patients. All patients received ablation therapy. The patients were followed up to observe tumor recurrence and death, and the patients without recurrence or death were followed up to September 2019. The two groups were compared in terms of complications after ablation, complete tumor response rate, tumor recurrence or progression, and postoperative survival. The two-independent-samples t-test was used for comparison of normally distributed continuous data between two groups; The Mann-Whitney U test was used for comparison of non- normally distributed continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups; the Kaplan-Meier method was used to analyze local tumor progression rate and cumulative survival rate, and the log-rank test was used for comparison between two groups.  Results  There were no significant differences in baseline levels between the two groups. There were no significant differences between the dangerous area group and the non-dangerous area group in the incidence rates of mild complications (42.5% vs 51.1%, χ2=1.002, P=0.317) and severe complications (6.0% vs 2.22%, χ2=0.453, P=0.290) and the reduction rate and normalization rate of alpha-fetoprotein within 1 month after ablation (reduction rate: 75.0% vs 80.0%, χ2=0.464, P=0.496; normalization rate: 33.9% vs 26.3%, χ2=0.381, P=0.537), and there was also no significant difference in complete tumor response rate between the two groups (91.8% vs 93.3%, P=0.990). The dangerous area group had 1- and 2-year progression-free survival rates of 60.7% and 37.1%, respectively, and the non-dangerous area group had 1- and 2-year progression-free survival rates of 63.5% and 55.0%, respectively, with a median progression-free survival time of 18 months and 27 months, respectively, and there was no significant difference between the two groups (χ2=0.573, P=0.449). The dangerous area group had 1- and 2-year cumulative survival rates of 96.8% and 90.3%, respectively, and the non-dangerous area group had 1- and 2-year cumulative survival rates of 93.3% and 87.8%, respectively, with no significant difference between the two groups (χ2=0.110, P=0.731).  Conclusion  Ultrasound-guided percutaneous local ablation is a feasible, safe, and effective method for the treatment of liver cancer in dangerous areas.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    Bureau of Medical AdministrationNational Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [2]
    LEE WC, JENG LB, CHEN MF. Estimation of prognosis after hepatectomy for hepatocellular carcinoma[J]. Br J Surg, 2002, 89(3): 311-316. DOI: 10.1046/j.0007-1323.2001.02034.x.
    [3]
    Bureau of Medical Administration National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [4]
    TOSHIMORI J, NOUSO K, NAKAMURA S, et al. Local recurrence and complications after percutaneous radiofrequency ablation of hepatocellular carcinoma: A retrospective cohort study focused on tumor location[J]. Acta Med Okayama, 2015, 69(4): 219-226. DOI: 10.18926/AMO/53558.
    [5]
    LEE CH, CHEN WT, LIN CC, et al. Radiofrequency ablation assisted by real-time virtual sonography for hepatocellular carcinoma inconspicuous under sonography and high-risk locations[J]. Kaohsiung J Med Sci, 2015, 31(8): 413-419. DOI: 10.1016/j.kjms.2015.06.002.
    [6]
    NAKAZAWA T, KOKUBU S, SHIBUYA A, et al. Radiofrequency ablation of hepatocellular carcinoma: Correlation between local tumor progression after ablation and ablative margin[J]. AJR Am J Roentgenol, 2007, 188(2): 480-488. DOI: 10.2214/AJR.05.2079.
    [7]
    JIANG C, LIU B, CHEN S, et al. Safety margin after radiofrequency ablation of hepatocellular carcinoma: Precise assessment with a three-dimensional reconstruction technique using CT imaging[J]. Int J Hyperthermia, 2018, 34(8): 1135-1141. DOI: 10.1080/02656736.2017.1411981.
    [8]
    Chinese Society of Liver Cancer, Chinese Anti-Cancer Association; Chinese Society of Clinical Oncology, Chinese Anti-Cancer Association; Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on the norms of local ablation therapy for hepatocellular carcinoma[J]. J Clin Hepatol, 2011, 27(3): 236-238, 244. http://lcgdbzz.org/article/id/LCGD201103004

    中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌学组. 肝癌局部消融治疗规范的专家共识[J]. 临床肝胆病杂志, 2011, 27(3): 236-238, 244. http://lcgdbzz.org/article/id/LCGD201103004
    [9]
    LENCIONI R, LLOVET JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60. DOI: 10.1055/s-0030-1247132.
    [10]
    BENSON AB 3rd, D'ANGELICA MI, ABBOTT DE, et al. NCCN guidelines insights: Hepatobiliary cancers, version 1.2017[J]. J Natl Compr Canc Netw, 2017, 15(5): 563-573. DOI: 10.6004/jnccn.2017.0059.
    [11]
    ZHU P, WANG YM. Updated key points and clinical pathway for NCCN clinical practice guidelines in oncology: Hepatobiliary cancers (Version2. 2016)[J]. J Clin Hepatol, 2016, 32(9): 1644-1652. DOI: 10.3969/j.issn.1001-5256.2016.09.003.

    朱鹏, 王宇明. 《2016年美国国立综合癌症网络肝胆肿瘤临床实践指南(V2版)》更新要点及临床路径[J]. 临床肝胆病杂志, 2016, 32(9): 1644-1652. DOI: 10.3969/j.issn.1001-5256.2016.09.003.
    [12]
    YANG BS, YUAN M, HOU YB, et al. TACE combined with precision radiofrequency ablation by using multiple imaging guidance technology for HCC located at exceptionalsites[J]. J Intervent Radiol, 2018, 27(12): 1193-1198. DOI: 10.3969/j.issn.1008-794X.2018.12.018.

    杨柏帅, 袁敏, 侯毅斌, 等. TACE联合多影像引导技术精准消融特殊部位肝细胞癌29例[J]. 介入放射学杂志, 2018, 27(12): 1193-1198. DOI: 10.3969/j.issn.1008-794X.2018.12.018.
    [13]
    HAN HY, JING X, DING JM, et al. Safety and efficacy of microwave ablation for hepatocellular carcinoma at dangerous locations[J]. Chin J Interv Imaging Ther, 2017, 14(4): 205-209. DOI: 10.13929/j.1672-8475.201611009.

    韩海云, 经翔, 丁建民, 等. 经皮微波消融治疗危险部位肝癌的安全性和疗效分析[J]. 中国介入影像与治疗学, 2017, 14(4): 205-209. DOI: 10.13929/j.1672-8475.201611009.
    [14]
    TERATANI T, YOSHIDA H, SHⅡNA S, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations[J]. Hepatology, 2006, 43(5): 1101-1108. DOI: 10.1002/hep.21164.
    [15]
    HUANG H, LIANG P, YU XL, et al. Safety assessment and therapeutic efficacy of percutaneous microwave ablation therapy combined with percutaneous ethanol injection for hepatocellular carcinoma adjacent to the gallbladder[J]. Int J Hyperthermia, 2015, 31(1): 40-47. DOI: 10.3109/02656736.2014.999017.
    [16]
    ZHANG M, LIANG P, CHENG ZG, et al. Efficacy and safety of artificial ascites in assisting percutaneous microwave ablation of hepatic tumours adjacent to the gastrointestinal tract[J]. Int J Hyperthermia, 2014, 30(2): 134-141. DOI: 10.3109/02656736.2014.891765.
    [17]
    WONG SN, LIN CJ, LIN CC, et al. Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations[J]. AJR Am J Roentgenol, 2008, 190(3): w187-w195. DOI: 10.2214/AJR.07.2537.
    [18]
    LIU A, XU W, XU H, et al. Effects of ultrasound-guided low-power microwave ablation for the treatment of liver cancer in special sites[J]. J Pract Radiol, 2018, 34(12): 1925-1928. DOI: 10.3969/j.issn.1002-1671.2018.12.028.

    柳昂, 许伟, 徐浩, 等. 超声引导下小功率微波消融术治疗特殊部位肝癌疗效分析[J]. 实用放射学杂志, 2018, 34(12): 1925-1928. DOI: 10.3969/j.issn.1002-1671.2018.12.028.
    [19]
    ZHANG NN, CHENG XJ, LIU JY, et al. High-powered microwave ablation in treating patients with hepatocellular carcinoma and the risk fac-tors of recurrence[J]. J Prac Hepatol, 2015, 18(3): 249-253. DOI: 10.3969/j.issn.1672-5069.2015.02.008.

    张宁宁, 程晓静, 刘建勇, 等. 大功率微波消融治疗肝癌临床疗效及其复发危险因素分析[J]. 实用肝脏病杂志, 2015, 18(3): 249-253. DOI: 10.3969/j.issn.1672-5069.2015.02.008.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (386) PDF downloads(51) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return